Back to Academy

Post-Market Clinical Follow-Up (PMCF): What Activities Are There?

Under the EU Medical Device Regulation (MDR) and the UK Medical Devices Regulations 2002 (UK MDR), medical device lifecycle management is a continuous cycle of collecting clinical data. Both regimes treat market access as the beginning, not the end, of clinical data collection. Post-market insight is split between two complementary mechanisms: post-market surveillance (PMS) and post-market clinical follow-up (PMCF).

PMCF is a focused activity on clinical safety and performance, while PMS is the overarching system for collecting all quality, performance and safety data. Together, PMCF and PMS are the MedTech counterpart to Phase IV post-marketing studies in pharmaceutical clinical trials.

This guide breaks down what MedTech manufacturers need to know about PMCF, including the difference between general and specific activities and how to build and draft PMCF plans and reports.

In short

  • What is PMCF? A continuous, proactive process to update the clinical evaluation of a medical device by collecting real-world clinical safety and performance data in human subjects.
  • Core objectives: Confirm an acceptable benefit-risk ratio, identify unknown long-term side effects, detect systematic misuse or off-label use, and substantiate clinical claims over the device's lifetime.
  • Legal basis: EU MDR 2017/745 (Annex XIV, Part B) and the UK MDR post-market surveillance framework.
  • Who is Ledidi? Ledidi is a Norwegian software company founded by academic surgeons and software engineers. We provide a unified, secure cloud platform, comprising Ledidi Core, Ledidi Trials and Ledidi Registries, that combines data capture, real-time analytics and global collaboration.

What is post-market clinical follow-up (PMCF) for medical devices?

Post-market clinical follow-up (PMCF) is a continuous and proactive process of collecting clinical data from the real-world use of a device after it has been placed on the market. It is the clinical arm of post-market surveillance (PMS). PMS is the broad quality system covering complaints, technical service records, sales volume and vigilance, while PMCF focuses specifically on patient safety, clinical efficacy and clinical outcomes.

The clinical arm of post-market surveillance

PMCF feeds clinical evidence into the PMS system. That evidence supports the continuous clinical evaluation of the device and must be incorporated into its technical documentation and Clinical Evaluation Report (CER).

Read more about post-market surveillance as a whole, and what goes into a PMS plan, in our guide to post-market surveillance.

PMCF is required under the EU MDR

PMCF is required under the EU MDR. Defined in Annex XIV, Part B, it is part of the clinical evaluation of every CE-marked device placed on the EU market, and a manufacturer can only leave out specific PMCF activities with a documented justification. In Great Britain, the post-market surveillance requirements in Part 4A of the UK MDR set equivalent expectations for clinical follow-up. The primary goals of PMCF are to monitor known risks, identify potential risks or side effects, and ensure an acceptable benefit-risk balance.

What PMCF activities are there? Comparing general and specific methods

Once a device is on the market and used by the general public, manufacturers can examine its effects through general or specific activities. These complementary strategies are set out in MDCG 2020-7, published by the Medical Device Coordination Group (MDCG).

General PMCF methods gather real-world information that already exists or reaches the manufacturer, such as published literature and user feedback. Specific methods are planned, structured data collections designed to answer defined clinical questions, such as PMCF studies, registries and protocol-driven surveys. The same method can fall on either side: an informal feedback questionnaire is a general activity, while a survey of patients or clinicians run to a PMCF protocol, with defined endpoints, a target sample and scheduled follow-up, is a specific activity.

Examples of general PMCF activities

  • Clinical user surveys: Standardised questionnaires sent to surgeons, nurses and technicians who can speak to the device's usability and ergonomics. Their structured feedback helps track performance throughout the device lifecycle. When a survey is run to a PMCF protocol with defined endpoints and scheduled follow-up, it becomes a specific PMCF activity.
  • Literature review: Screening scientific databases to identify new clinical data on the device, on equivalent or similar devices and on the state of the art, including emerging risks.
  • Professional feedback: Direct clinical insights on device performance from user case discussions and general feedback at conferences or similar professional networks.

Examples of specific PMCF activities

  • Clinical device registries: Enrolling patients in high-quality clinical registries that capture long-term outcomes or rare complications in large, heterogeneous patient populations over many years. Registries are an established PMCF route, particularly for orphan, breakthrough and high-risk devices, but their value depends on the quality and completeness of the data entered.
  • Prospective PMCF clinical investigations: Formal, protocol-driven post-market clinical studies in human subjects, within the device's CE-marked or UKCA-approved intended purpose. They are often expected for high-risk devices (Class III and implantable) when the clinical evaluation identifies gaps that other methods cannot close.
  • Retrospective cohort studies: Structured analyses of existing patient medical records and electronic health data from hospitals where the device has routinely been used.
  • Protocol-driven patient and clinician surveys: Questionnaires, including patient-reported outcome measures (PROMs), sent to defined patient or clinician groups at scheduled follow-up points under a PMCF protocol. They are a practical way to collect structured clinical data at scale, particularly for lower-risk devices and for outcomes that patients report best.

Developing a post-market clinical follow-up plan (PMCF plan)

A PMCF plan sets out the strategy and methods you will use to gather clinical data. That data can include everything from user surveys and registry data to literature reviews and formal PMCF studies. The crucial element is to argue why each method and data source has been selected, and to explain how each aligns with the safety and performance requirements of the device in question.

Objectives of a PMCF plan

  • Confirm the safety and performance of the device throughout its expected lifetime.
  • Identify previously unknown side effects, and document known side effects.
  • Identify and analyse emerging risks.
  • Ensure an acceptable balance between the benefits and risks of the device.
  • Identify possible systematic misuse or off-label use of the device.

What must a PMCF plan contain?

As outlined in EU MDR Annex XIV Part B and MDCG 2020-7, a compliant PMCF plan must contain the following components:

Scope, device description, risk classification and intended purpose

The basic details of the device: trade name, model, risk classification (Class I to Class III, or IVD), Unique Device Identifier (UDI), and the exact intended clinical purpose as defined in the Instructions for Use (IFU).

Identified clinical evidence gaps and residual risks

The unanswered clinical questions and potential risks of the device, taken from the Clinical Evaluation Report (CER) and the risk management file, must be summarised concisely in the plan.

Justification of methods, endpoints and statistics

A scientific justification explaining why the selected general and specific activities are proportionate to the device's risk class, novelty and clinical claims.

For specific studies and registries, the plan must document statistical power calculations, predefined primary and secondary endpoints, and acceptable clinical thresholds.

Milestones and timeline

A clear operational roadmap covering patient recruitment schedules, follow-up intervals, data analysis cut-off dates and submission deadlines for the PMCF Evaluation Report.

The PMCF plan must be included in the post-market surveillance (PMS) plan.

PMCF plan template

The Medical Device Coordination Group (MDCG) has published a template that covers all the content elements of a PMCF plan. It is structured into the following sections:

  • Section A: Manufacturer contact details
  • Section B: Medical device description and specification
  • Section C: Activities related to PMCF, including general and specific methods and procedures
  • Section D: Reference to the relevant parts of the technical documentation
  • Section E: Evaluation of clinical data relating to equivalent or similar devices
  • Section F: Reference to any applicable common specifications, harmonised standards or guidance documents
  • Section G: Estimated date of the PMCF evaluation report

Download the template directly from the MDCG (PDF).

Summarise findings in a PMCF evaluation report

The results of the PMCF activities must be summarised in a PMCF evaluation report. The report analyses whether the collected data confirms the device's safety, clinical performance and acceptable benefit-risk ratio.

The PMCF report does not sit in isolation. It feeds directly into the Clinical Evaluation Report (CER), so that clinical evidence is continuously updated throughout the product lifecycle. Depending on the device, the report is updated at least annually (Class III and implantable devices) or, for other devices, typically every 2 to 5 years.

For Class IIa, IIb and Class III devices, conclusions are incorporated into the Periodic Safety Update Report (PSUR). For Class III and implantable devices, the PSUR is submitted to the notified or approved body. For other Class IIa and IIb devices, it is kept available for the notified or approved body to review. For Class I devices, findings support the Post-Market Surveillance Report (PMSR).

PMCF report template

The MDCG has also published a template that covers all the content elements of a PMCF evaluation report. It is structured into the following sections:

  • Section A: Manufacturer contact details
  • Section B: Medical device description and specification
  • Section C: Activities undertaken related to PMCF results
  • Section D: Evaluation of clinical data relating to equivalent or similar devices
  • Section E: Impact of the results on the technical documentation
  • Section F: Reference to any common specifications, harmonised standards or guidance documents
  • Section G: Conclusions

Download the template directly from the MDCG (PDF).

PMCF under EU MDR and UK MDR: what UK manufacturers must know

PMCF is required under the EU MDR to ensure oversight of the safety and performance of medical devices. In the United Kingdom, the Medical Devices Regulations 2002 (UK MDR) play the corresponding role. Post-market requirements, including PMCF, are set out in Part 4A of the UK MDR, which has applied since 16 June 2025 and is enforced by the Medicines and Healthcare products Regulatory Agency (MHRA).

The MHRA requires manufacturers to maintain a post-market surveillance plan that includes the PMCF activities needed for continuous, proactive evaluation of clinical data. This covers general activities (such as screening medical literature and analysing user feedback) and specific methods (such as dedicated PMCF studies and tracking data from clinical registries).

Manufacturers document their strategy in a PMCF plan, analyse the findings and feed them into the CER. Depending on device risk class, findings are summarised in a PMSR or PSUR, which must be made available to the MHRA on request and, for the highest-risk devices, submitted to the UK approved body.

On 21 October 2026, the UK government confirmed that CE-marked devices will be accepted in Great Britain indefinitely. Manufacturers of CE-marked devices can therefore run a single PMCF programme for the EU and GB markets, as long as it also meets the Part 4A post-market requirements.

What notified bodies and experts expect from PMCF in 2026

At the MedTech Summit in Berlin in June 2026, notified bodies, expert-panel reviewers and consultants described how PMCF expectations are changing in practice:

  • PMCF must always be considered. Every device needs a documented position on PMCF. Even when the conclusion is that no specific activity is needed, that decision must be justified.
  • Evidence gaps should drive the plan. Each gap identified in the clinical evaluation report should map to a PMCF activity. A clinical evaluation plan that has visibly been written after the report is treated as a major non-conformity.
  • Expert panels are asking for more follow-up. In an analysis of 18 published opinions from the EU expert panels, presented by a former notified body assessor, half required additional PMCF, including one for a device supported by a randomised controlled trial.
  • Indirect PMCF can work for legacy devices. For devices with no direct clinical benefit, such as some reusable surgical instruments, notified bodies have accepted indirect PMCF built from several data sources, provided the logic behind each source is documented.
  • Orphan devices move the evidence burden after launch. For devices intended for very small patient populations (MDCG 2024-10), regulators accept less pre-market data in exchange for proportionate post-market follow-up, typically through a registry.

From PMCF plan to live data: Ledidi and Mantra Systems

PMCF programmes often break down between the plan and the data. A regulatory consultant writes the PMCF plan, and the data is then collected with a generic survey tool and spreadsheets, which makes follow-up hard to manage and the evaluation report slow to write.

To close that gap, Ledidi has partnered with Mantra Systems, a Sheffield-based regulatory consultancy where clinicians and regulatory specialists work in the same team. Mantra Systems supports manufacturers with UK and EU MDR and IVDR market access, clinical evaluation and PMCF, and has worked with more than 500 clients.

The work is divided by expertise. Mantra Systems designs the PMCF strategy, protocol and questionnaires, and writes the PMCF evaluation report for the technical documentation. Ledidi handles enrolment, automated follow-up at the planned intervals, monitoring, audit trail, analysis and export. Patients and clinicians complete the surveys in Ledidi, follow-ups go out on schedule, and the evaluation report is written from a live, structured dataset.

"Designing a PMCF study is one thing. Making it successful in practice is another. What’s often missing is execution — whether it’s datapoint optimisation or a data collection system that works seamlessly."
Paul Hercock, CEO, Mantra Systems

The importance of audit-ready clinical data infrastructure

Medical device manufacturers need flexible infrastructure for clinical data that keeps them compliant without slowing the business down. A prime example of PMCF in practice is CMR Surgical, developer of the Versius surgical robotic system, which used Ledidi Core to track clinical results across multiple NHS hospitals. CMR's global real-world data registry, which also runs on Ledidi, is covered in our guide to post-market surveillance.

On Ledidi's secure, cloud-based platform, surgical teams and clinical researchers can collaborate in real time, entering post-operative clinical data into standardised electronic case report forms (eCRFs). For CMR Surgical, this infrastructure is vital for running multicentre prospective clinical trials.

Read the full customer success story

Explore the topic further

Frequently asked questions

Can a manufacturer opt out of PMCF?

Under EU MDR Annex III and Annex XIV Part B, a manufacturer can only opt out of PMCF with a rigorous, documented justification in the post-market surveillance plan, reflected in the Clinical Evaluation Report (CER). The justification must show that pre-market clinical investigations and standard post-market surveillance are fully sufficient to verify safety and performance. Notified bodies expect PMCF to be considered for every device, even when the conclusion is that no specific activity is needed.

Is a clinician survey enough for PMCF?

Clinical user surveys are an accepted general PMCF method, but a plan that relies only on informal user surveys is rarely sufficient for medium- to high-risk devices (Class IIb, Class III and implantables). Higher-risk devices need specific PMCF activities, such as clinical registries, protocol-driven patient or clinician surveys or prospective PMCF studies, to generate statistically sound clinical evidence.

How does PMCF relate to Phase IV clinical trials?

In pharmaceutical development, Phase IV trials evaluate approved drugs under real-world conditions to monitor rare side effects and long-term efficacy. In MedTech, PMCF plays a similar role: it generates prospective, real-world clinical evidence after market authorisation to verify that the device performs safely across broader, more varied patient populations over its entire lifecycle.

Sources

More From Ledidi Academy